Home
Medical Courses
Webinars
Self-development
My Activity
RAAS Fact Checking Module 2

RAAS Fact Checking Module 2

General PracticeInternal MedicineFamily MedicineCardiologyEndocrinology
A badge with ribbon in color black CPD Unit: 1 Point | An analog clock in color black 41 Minutes | A black calendar with white triangle in center that has a black exclamation point in the middle 31 Jul 2025 
Back to courses list

Overview

About

The renin-angiotensin aldosterone system is the therapeutic target of first-line antihypertensive medications angiotensin-converting enzyme inhibitors (ACEi) and the angiotensin receptor blockers (ARBs). Comparison of the effects of these drugs on various clinical parameters will be the focus of the discussions in this course. The two lectures in this module will cover Hypertension in Special Population: DIABETES and How We Can Explain the Differences Between ACEi and ARB: Focus on Pathophysiology.

Learning Objectives:

  1. Explain the influence of hypertension and diabetes on cardiovascular disease, including the importance of tight control of blood pressure in patients with diabetes
  2. Evaluate the evidence for ACEi and ARBs in patients with hypertension and diabetes on cardiovascular morbidity and mortality
  3. Evaluate the evidence of for ACEi and ARBs in preventing chronic kidney disease in patients with diabetes who are at high cardiovascular risk
  4. Explain the difference in pathophysiology of ACEi and ARBs on angiotensin II receptors, bradykinin, and nitric oxide production
  5. Discuss the evidence for ACEis and ARBs on endothelium function, fibrinolysis and cardiac protection
  6. Consider the clinical implications of the difference in basic science between ACEi and ARb

Topics covered

  1. Fact check on hypertension and obesity increasing the risk of vascular complications in diabetes
  2. Fact check whether control of blood pressure prevents cardiovascular morbidity and mortality in patients with diabetes
  3. Fact check whether ACEi reduced all-cause mortality, CV mortality, and major CV events in patients with Type 2 diabetes whereas ARB had no benefits on these outcomes
  4. Fact check whether ARBs are superior to ACEi for the prevention of chronic kidney disease in patients with diabetes who have high CV risk.
  5. Fact check whether patients with hypertension and diabetes are considered moderate to high risk patients and should be treated with a RAAS and CCB or diuretic
  6. Fact check whether ACEi and ARBs have different actions on the renin-angiotenin system.
  7. Fact check whether ACEi and ARB have different kinds of effect on endothelium function.
  8. ACEi and ARBs affect fibrinolysis differently.

Speaker: Dr. Bien Matawaran, MD, FPCP, FPCEDM
Chief, Section of Endocrinology, Diabetes and Metabolism
University of Sto. Tomas Hospital

Keywords: hypertension, diabetes, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker

1 CPD Point Available

  • Score at least 80% on the quiz.
  • A certificate can be downloaded upon successful completion. Please use the information on the certificate to claim your CPD points.
Something went wrong.